Travere Therapeutics (NASDAQ:TVTX) Price Target Raised to $19.00

Travere Therapeutics (NASDAQ:TVTX) had its price target boosted by HC Wainwright from $17.00 to $19.00 in a research note issued to investors on Wednesday, Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Travere Therapeutics’ FY2025 earnings at ($1.80) EPS, FY2026 earnings at $0.20 EPS, FY2027 earnings at $1.98 EPS and FY2028 earnings at $4.29 EPS.

TVTX has been the topic of several other reports. Piper Sandler boosted their price objective on Travere Therapeutics from $10.00 to $11.00 and gave the company a neutral rating in a research report on Thursday, January 18th. Wells Fargo & Company lifted their target price on Travere Therapeutics from $8.00 to $9.00 and gave the stock an equal weight rating in a report on Friday, February 16th. Wedbush reaffirmed an outperform rating and issued a $13.00 target price on shares of Travere Therapeutics in a report on Wednesday, April 17th. Finally, Guggenheim reaffirmed a neutral rating on shares of Travere Therapeutics in a report on Wednesday, March 27th. Six equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, Travere Therapeutics has a consensus rating of Moderate Buy and an average price target of $18.00.

Travere Therapeutics Price Performance

Shares of Travere Therapeutics stock opened at $5.26 on Wednesday. The stock’s 50-day simple moving average is $7.28 and its 200-day simple moving average is $7.65. Travere Therapeutics has a 52 week low of $5.12 and a 52 week high of $22.75. The company has a market capitalization of $400.34 million, a price-to-earnings ratio of -3.27 and a beta of 0.58. The company has a quick ratio of 3.41, a current ratio of 3.47 and a debt-to-equity ratio of 1.88.

Travere Therapeutics (NASDAQ:TVTX) last announced its quarterly earnings data on Thursday, February 15th. The company reported ($1.16) EPS for the quarter, beating the consensus estimate of ($1.27) by $0.11. Travere Therapeutics had a negative return on equity of 177.97% and a negative net margin of 56.02%. The business had revenue of $45.06 million for the quarter, compared to the consensus estimate of $41.25 million. As a group, analysts expect that Travere Therapeutics will post -3.1 earnings per share for the current fiscal year.

Insider Buying and Selling at Travere Therapeutics

In other Travere Therapeutics news, insider Peter Heerma sold 4,195 shares of the business’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $8.53, for a total transaction of $35,783.35. Following the completion of the transaction, the insider now owns 99,503 shares in the company, valued at $848,760.59. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, insider Peter Heerma sold 4,195 shares of the business’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $8.53, for a total value of $35,783.35. Following the completion of the sale, the insider now owns 99,503 shares in the company, valued at $848,760.59. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Christopher R. Cline sold 3,818 shares of the business’s stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $8.53, for a total value of $32,567.54. Following the completion of the sale, the chief financial officer now owns 70,903 shares of the company’s stock, valued at approximately $604,802.59. The disclosure for this sale can be found here. Insiders sold 34,773 shares of company stock worth $300,625 over the last 90 days. Company insiders own 3.75% of the company’s stock.

Institutional Trading of Travere Therapeutics

A number of large investors have recently modified their holdings of the company. Armistice Capital LLC boosted its holdings in shares of Travere Therapeutics by 0.7% in the third quarter. Armistice Capital LLC now owns 7,500,000 shares of the company’s stock valued at $67,050,000 after purchasing an additional 50,000 shares during the period. Vanguard Group Inc. lifted its holdings in Travere Therapeutics by 10.9% during the third quarter. Vanguard Group Inc. now owns 4,667,458 shares of the company’s stock worth $41,727,000 after buying an additional 460,176 shares during the period. Kynam Capital Management LP lifted its holdings in Travere Therapeutics by 105.6% during the fourth quarter. Kynam Capital Management LP now owns 2,000,000 shares of the company’s stock worth $17,980,000 after buying an additional 1,027,398 shares during the period. Jacobs Levy Equity Management Inc. lifted its holdings in Travere Therapeutics by 9.6% during the third quarter. Jacobs Levy Equity Management Inc. now owns 1,671,770 shares of the company’s stock worth $14,946,000 after buying an additional 146,970 shares during the period. Finally, Finepoint Capital LP lifted its holdings in Travere Therapeutics by 60.2% during the fourth quarter. Finepoint Capital LP now owns 1,435,321 shares of the company’s stock worth $12,904,000 after buying an additional 539,500 shares during the period.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.